Week in Review: Cannabis & Psychedelics Industry Highlights

LOS ANGELES – The U.S. Cannabis sector has settled into a phase defined by operational discipline rather than continued expansion. While mature markets continue to generate reliable revenues, wholesale price compression and margin erosion have forced some operators to consolidate assets, close underperforming facilities, and sharpen their focus on boosting efficiency. At the same time, state lawmakers are advancing targeted policy changes that expand patient access, clarify hemp regulations, and pilot new consumption models – practical steps that reduce uncertainty without overhauling the existing framework.

Internationally, medical Cannabis programs are expanding in a measured way, with established players adding product lines in regulated markets, while psychedelics are attracting selective capital and early regulatory nods in Europe as companies pursue therapies for unmet mental-health needs.

Scroll down to observe these milestones in action and access the complete analysis of financial performance, key transactions, regulatory developments, global expansion, and what these developments mean for operators and investors heading into 2026.

1. Corporate Earnings Deliver Key Insights

This earnings season provided a realistic snapshot of how Cannabis operators in the U.S. and Canada are navigating an established market defined by compressed wholesale prices, intense competition, and the need for operational efficiency.

Vireo Growth posted Q4 and FY 2025 revenue of $104.5 million with adjusted EBITDA of $29.5 million at a 28.2% margin, supported by acquisition integrations and 22% pro forma same-store sales growth.

High Tide set new records in Q1 2026 with revenue of $178.3 million, gross profit of $44.4 million, adjusted EBITDA up 62% to $11.5 million, and positive free cash flow of $2.9 million, driven by its Canadian discount-retail model.

Rubicon Organics disclosed FY 2025 net revenue of $59.5 million, up 22% year-over-year, and delivered its first full-year net income of $1.1 million along with adjusted EBITDA of $5 million.

Glass House Brands reported its full-year revenue of $182 million and adjusted EBITDA of $17 million, while maintaining retail momentum and issuing 2026 guidance targeting $235-245 million in revenue.

Auxly posted full-year 2025 net revenue of $151.5 million, up 24%, with adjusted EBITDA rising 64% to $43.8 million and net income of $41.9 million.

LEEF Brands detailed its performance for Q4 and FY 2025, reporting revenue of $34.8 million, up 22.1%, a narrowed adjusted EBITDA loss of $0.4 million, improved free cash flow while highlighting cost savings from vertical integration.

2. Strategic Moves & Consolidations

Deal activity and facility decisions reflect ongoing consolidation driven by margin realities. Mergers and acquisitions that add scale or patient access offer potential efficiencies, while exits and closures highlight the difficult economics facing certain assets in oversupplied wholesale environments. The pattern reveals capital flowing toward operators with clearer paths to sustainable performance.

Canopy Growth finalized its purchase of MTL Cannabis, issuing approximately 41.2 million shares and C$18.5 million in cash.

Vireo Growth closed its acquisition of Schwazze assets, expanding its retail and manufacturing presence in Colorado and New Mexico.

Kiva Sales & Service and Petalfast signed a letter of intent to merge their California distribution operations, aiming to create a more robust platform with enhanced sales capabilities and technology tools.

Cannabist completed transactions to divest its operations in Ohio and Delaware, allowing the company to concentrate resources on higher-priority markets.

PharmaCann announced the permanent closure of its large Denver cultivation facility in response to ongoing wholesale price compression.

Cheech and Chong secured a distribution agreement with Breakthru to broaden availability of their branded products.

3. Regulatory & Policy Developments

Policy activity remains incremental and state-driven, focusing on practical adjustments such as patient reciprocity, hemp clarity, and limited on-site consumption. These steps can ease operational friction and support licensed businesses, yet broader federal resolution on hemp and interstate commerce remains absent, leaving operators to manage a fragmented regulatory environment.

The New York Senate Health Committee advanced legislation that would recognize out-of-state medical Cannabis certifications, enabling qualifying non-resident patients to purchase at licensed dispensaries.

Ohio rolled out updated Cannabis and hemp regulations following the failure of a recent referendum effort, including potency caps and restrictions directing higher-THC hemp products through licensed retailers.

The South Carolina Senate passed a measure to preserve legal status for hemp-derived THC drinks and gummies, with defined potency limits and sales parameters.

San Francisco introduced an ordinance that would permit licensed Cannabis retailers to operate on-site consumption cafes serving food and non-alcoholic beverages.

A bipartisan proposal to delay the federal hemp ban has attracted 36 sponsors in Congress, providing additional adjustment time for producers.

The Wine & Spirits Wholesalers of America released a new educational guide to help members navigate hemp beverage regulations.

Convenience stores continue offering hemp-derived products as they adapt to evolving regulatory oversight and anticipate the November hemp ban.

4. Psychedelics Sector Progress

Developments in psychedelics stay cautious and data-focused, with regulatory designations and targeted capital raises indicating growing but selective institutional interest. Early programs emphasize safety and measurable outcomes, reflecting the sector’s need to build credible clinical and regulatory foundations before wider adoption.

Massachusetts legislators continued advancing measures to establish supervised psychedelic therapy programs with strict oversight and data collection requirements.

AbbVie obtained the inaugural PRIME designation from the European Medicines Agency (EMA) for its investigational psychedelic candidate targeting major depressive disorder.

Gilgamesh Pharmaceuticals secured $60 million in funding to advance its neuropsychiatric development pipeline.

HCN Insight

These developments paint a picture of an industry that has moved beyond expansion into a phase defined by measured execution and strategic positioning. Sales milestones and earnings reports confirm pockets of resilient demand and improving margins where the industry players have streamlined operations, yet facility closures and strategic exits reveal persistent challenges from price pressure and oversupply.

Consolidation activity signals capital reallocating toward scale and focus, while regulatory tweaks at the state level provide incremental breathing room without resolving deeper structural issues such as federal banking limitations or interstate commerce barriers. Psychedelics continue their slow institutional integration, and international medical markets remain a secondary growth avenue rather than a near-term savior. The Whitney Economics outlook for 2026 offers cautious optimism, but delivery will largely depend on whether more companies can translate disciplined execution into consistent free cash flow.

For now, the Cannabis and Psychedelics sectors reward patience, operational rigor, and selective capital deployment over broad enthusiasm. Those positioned with strong balance sheets and clear strategies stand the best chance of navigating the current environment and capturing value as conditions gradually stabilize.